Generated: December 10, 2017
DrugPatentWatch Database Preview
Details for Patent: 5,217,974
« Back to Dashboard
Summary for Patent: 5,217,974
|Title:|| Method for treating gar-transformylase tumors in mammals and reducing mammalian toxicity|
|Abstract:||Administration of a folate binding protein binding agent in conjunction with use of an antitumor agent which is an inhibitor of glycinamide ribonucleotide transformylase or other antifolate reduces the toxic effects of such agent and provides an enhanced therapeutic index.|
|Inventor(s):|| Grindey; Gerald B. (Indianapolis, IN), Shih; Chuan (Carmel, IN) |
|Assignee:|| Eli Lilly and Company (Indianapolis, IN) |
Patent Claim Types:|
see list of patent claims
No matches for this query
International Patent Family for Patent: 5,217,974
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws,
it is advisable to have patent counsel verify freedom to operate.
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.